INNATE PHARMA SA ADR
WKN: A2PSSH | ISIN: US45781K2042 | Ticker-Symbol: IDDASiehe auch INNATE PHARMA SA
Frankfurt
17.07.26 | 15:25
1,390 Euro
-2,80 % -0,040
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,490 | 1,580 | 17.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.05. | Innate Pharma SA - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 22.05. | Innate Pharma SA: Outcome of Innate Pharma's 2026 Annual General Meeting | 403 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced the voting results of its shareholders at the Annual General Meeting ("AGM"), which took... ► Artikel lesen | |
| INNATE PHARMA SA ADR Aktie jetzt für 0€ handeln | |||||
| 19.05. | Innate Pharma SA: Innate Pharma to participate in the Jefferies Global Healthcare Conference | 462 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced... ► Artikel lesen | |
| 16.05. | Innate Pharma übertrifft Erwartungen - Aktie steigt vorbörslich um fast 60 % | 4 | Investing.com Deutsch | ||
| 13.05. | Innate Pharma SA - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 13.05. | Innate Pharma reports Q1 results | 8 | Seeking Alpha | ||
| 13.05. | Innate Pharma SA: Innate Pharma Reports First Quarter 2026 Business Update and Financial Results | 652 | Business Wire | Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) remains planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation... ► Artikel lesen | |
| 12.05. | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026 | 346 | Business Wire | Regulatory News:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| 06.05. | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 06.05. | Innate Pharma SA: Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update | 396 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announces that the Company will hold a conference call on Wednesday, May 13, 2026 at 1:30... ► Artikel lesen | |
| 23.04. | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 23.04. | Innate Pharma SA: Innate Pharma to Participate in the D. Boral Capital Global Conference | 354 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced... ► Artikel lesen | |
| 17.04. | Innate Pharma legt Zwischenergebnisse zu Lungenkrebsstudie vor | 1 | Investing.com Deutsch | ||
| 17.04. | Innate Pharma reports interim lung cancer trial results | 1 | Investing.com | ||
| 17.04. | Innate Pharma SA: Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026 | 568 | Business Wire | Encouraging early results catalyze continued investigation in the MATISSE Phase 2 study evaluating IPH5201, a first-in-class anti-CD39 monoclonal antibody, in combination with durvalumab and... ► Artikel lesen | |
| 13.04. | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 13.04. | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026 | 397 | Business Wire | Regulatory News:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| 13.04. | Innate Pharma SA: Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026 | 386 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") will hold its Annual General Meeting of shareholders ("AGM") at 10:30 a.m. CEST on May 21, 2026... ► Artikel lesen | |
| 08.04. | Innate Pharma SA: Innate Pharma to Present at the AACR 2026 Oncology Industry Partnering Event | 396 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), announced today that Yannis Morel, Chief Operating Officer, will present at the AACR Oncology... ► Artikel lesen | |
| 03.04. | Innate Pharma SA: Innate Pharma to Participate in the Kempen Life Sciences Conference | 700 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced... ► Artikel lesen |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIVORYON THERAPEUTICS | 1,170 | -2,09 % | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update
Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented... ► Artikel lesen | |
| TME PHARMA | 0,064 | +5,47 % | TME Pharma NV: Minutes of the TME Pharma Annual General Meeting | Minutes of the TME Pharma Annual General Meeting Berlin, Germany, June 17, 2026, 6:30 p.m. CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing... ► Artikel lesen | |
| CANSINO BIOLOGICS | 2,700 | -3,57 % | CanSino Biologics Inc: CanSinoBIO's MCV4 Receives Registration Approval in Argentina, Further Expanding International Presence in South America | HONG KONG, June 29, 2026 - (ACN Newswire) - On June 25, CanSino Biologics Inc. (SSE: 688185, HKEX: 06185) announced that the Company's ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197)... ► Artikel lesen | |
| KARYOPHARM | 8,200 | -0,61 % | Karyopharm Therapeutics Inc.: Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment | - Completed Enrollment of Phase 3 XPORT-EC-042 Trial in Endometrial Cancer; Topline Data Expected Mid-2026 -
- Phase 3 SENTRY Results Selected for Late-Breaking... ► Artikel lesen | |
| MEREO BIOPHARMA | 0,274 | -2,14 % | Mereo BioPharma Group plc: Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates | LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial... ► Artikel lesen | |
| ADICET BIO | 6,900 | -4,17 % | Adicet Bio, Inc. - 8-K, Current Report | ||
| ANNOVIS BIO | 1,486 | -2,11 % | Annovis Bio Inc.: Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer | MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy... ► Artikel lesen | |
| INTEGRA LIFESCIENCES | 16,800 | -3,45 % | Integra LifeSciences Holdings Corporation: Integra LifeSciences Appoints Topaz Kirlew Chief Regulatory Officer | PRINCETON, N.J., July 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced the appointment of Topaz Kirlew... ► Artikel lesen | |
| RHYTHM PHARMACEUTICALS | 94,00 | +1,62 % | Citizens reiterates Rhythm Pharmaceuticals stock rating on strong Imcivree launch data | ||
| NEUPHORIA THERAPEUTICS | 3,415 | -0,44 % | Neuphoria Therapeutics, Inc.: Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc | Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria"... ► Artikel lesen | |
| RECCE PHARMACEUTICALS | 0,206 | +0,98 % | RECCE PHARMACEUTICALS LTD: Vietnamese Patent Granted for RECCE Anti-Infectives | ||
| MABION | 1,674 | +1,95 % | Mabion Enters Rare Disease Collaboration with Oddifact | ||
| QIAGEN | 35,965 | -0,55 % | Qiagen: Die Gerüchte gehen in die zweite Runde | Im Januar wurde gemunkelt, Qiagen könnte unmittelbar vor einer Übernahme stehen. Doch am Ende verlief die Sache im Sand. Die Aktie, die damals einen Riesensatz nach oben gemacht hatte, fiel tiefer als... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 133,99 | -0,07 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| ERASCA | 19,160 | +0,74 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen |
Das Unternehmen INNATE PHARMA SA ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,040 (-2,80 %) liegt der Kurs bei 1,390 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INNATE PHARMA SA ADR finden Sie auf Wallstreet Online.